Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H15Cl3N2OS |
Molecular Weight | 437.77 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC(Cl)=C(C=C1)[C@H](CN2C=CN=C2)OCC3=CSC4=C(Cl)C=CC=C34
InChI
InChIKey=JLGKQTAYUIMGRK-IBGZPJMESA-N
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2/t19-/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1780 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ERTACZO Approved UseERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section). Launch Date2003 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43.31 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
SERTACONAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. | 1992 May |
|
In vitro antifungal activity of sertaconazole. | 1992 May |
|
In vitro activity of sertaconazole. | 1992 May |
|
In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. | 1995 Oct |
|
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. | 1996 Mar-Apr |
|
Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. | 1997 Nov-Dec |
Sample Use Guides
Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395851
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
PR82C5R514
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
83685
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
DTXSID00207032
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL1410877
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
8554
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
300000036865
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
6604451
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
583057-48-1
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY | |||
|
C79926
Created by
admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY